Esophageal Cancer Market Analysis, Demand And Outlook 2025- 2034

Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence

What Is the Current Size and Annual Growth Rate of the Esophageal Cancer Market?
The esophageal cancer market size has grown strongly in recent years. It will grow from $1.39 billion in 2024 to $1.51 billion in 2025 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increased number of cancers, improvement in healthcare infrastructure, rise in alcohol consumption, growth in demand for preventive healthcare solutions, increase in prevalence of esophageal adenocarcinoma.

The esophageal cancer market size is expected to see strong growth in the next few years. It will grow to " $2.16 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to rising prevalence of esophageal cancer, increasing public understanding of healthcare, improvements in healthcare infrastructure, chronic consumption of smoking and alcohol, increasing prevalence of esophageal adenocarcinoma. Major trends in the forecast period include technological advancements in treatment options, increased investment in research and development, increasing utilization of precision medicine, development of targeted therapies, increased participation in clinical trials and collaborations between academia, pharmaceutical companies, and healthcare institutions.

Get your free report sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12637&type=smp

Which Market Forces Are Stimulating Growth in the Esophageal Cancer Market?
An increase in esophageal cancer is expected to propel the esophageal cancer market growth. Esophageal cancer is a malignancy that affects the esophagus, the tube-like structure connecting the throat to the stomach. As the incidence of esophageal cancer increases, there will be a higher demand for diagnostic procedures, such as endoscopy, imaging tests, and biopsies, to detect and confirm the presence of the disease. For instance, according to the American Cancer Society, a US-based professional organizations company, in 2023, there were 16,120 new deaths from esophageal cancer, and this number is projected to rise to 16,130 in 2024. Therefore, the increase in esophageal cancer is expected to drive the growth of the esophageal cancer market.

What Are the Emerging Segments Driving Growth in the Esophageal Cancer Market?
The esophageal cancermarket covered in this report is segmented –

1) By Type: Esophageal Squamous-Cell Carcinoma; Esophageal Adenocarcinoma; Other Types
2) By Treatment Type: Chemotherapy; Targeted Therapy; Other Treatment Types
3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
5) By End Users: Hospitals; Homecare; Specialty Centers; Other End Users

Subsegments:
1) By Esophageal Squamous-Cell Carcinoma: Localized Squamous-Cell Carcinoma; Advanced Squamous-Cell Carcinoma
2) By Esophageal Adenocarcinoma: Localized Adenocarcinoma; Advanced Adenocarcinoma
3) By Other Types: Neuroendocrine Tumors; Sarcomas; Mixed Cell Type Carcinomas

What Are the Current Trends Influencing the Esophageal Cancer Market?
New drug approval is a key trend gaining popularity in the esophageal cancer market. Major companies operating in the esophageal cancer market are focused on obtaining new drug approvals to strengthen their position and gain a competitive advantage. For instance, in May 2022, Bristol Myers Squibb, a US-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for its two products, including Opdivo (nivolumab) (injection for intravenous use) and Opdivo plus Yervoy (ipilimumab). Its primary therapeutic approaches are for individuals diagnosed with advanced or metastatic esophageal squamous cell carcinoma (ESCC). The authorization was granted following the Phase 3 clinical trial evaluation, which demonstrated enhanced overall survival rates among patients who received these medications.

Which Companies Are Expanding Their Presence in the Esophageal Cancer Market?
Major companies operating in the esophageal cancer market include Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Servier Pharmaceuticals, Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Ipsen SA, Dr. Reddy's Laboratories Ltd., Seagen Inc., Exelixis Inc., BeiGene Ltd., Clovis Oncology Inc., Aslan Pharmaceuticals Ltd.

Get the detailed esophageal cancer market report today
https://www.thebusinessresearchcompany.com/report/esophageal-cancer-global-market-report

Which Regional Markets Offer the Most Promising Growth Opportunities for the Esophageal Cancer Market?
North America was the largest region in the esophageal cancer market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the esophageal cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company